Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Guerry

Executive Summary

Chattem chairman and president died suddenly on May 23 at the age of 72. Guerry had served on the Chattem board of directors since 1955, and held the title of president since 1958 and chairman of the board since 1959. His son, Zan Guerry, holds the title of corporate exec VP and president-Chattem Consumer Products. The family has requested that contributions be made to the Alex Guerry Memorial Fund, Baylor School. P.O. Box 1337, Chattanooga, TN 37401. Alex Guerry held 18% of Chattem stock. The Guerry family, officer and directors of the company hold over 47% of Chattem stock.

You may also be interested in...



Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.

Amneal’s Generics Business Reinvigorated By New Launches

As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.

Medtech SMEs See Opportunities In UK Budget Of Few Surprises

Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel